Commonwealth Equity Services LLC Has $718,000 Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Commonwealth Equity Services LLC lowered its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 21.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,794 shares of the medical instruments supplier’s stock after selling 2,171 shares during the quarter. Commonwealth Equity Services LLC’s holdings in LeMaitre Vascular were worth $718,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. New York State Teachers Retirement System increased its holdings in shares of LeMaitre Vascular by 1.2% during the fourth quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier’s stock worth $755,000 after buying an additional 100 shares in the last quarter. Flputnam Investment Management Co. grew its position in LeMaitre Vascular by 3.6% during the 4th quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier’s stock worth $269,000 after acquiring an additional 102 shares during the last quarter. Norden Group LLC increased its holdings in LeMaitre Vascular by 4.5% during the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier’s stock valued at $218,000 after purchasing an additional 103 shares in the last quarter. Blue Barn Wealth LLC boosted its stake in LeMaitre Vascular by 4.4% in the fourth quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier’s stock worth $229,000 after purchasing an additional 104 shares in the last quarter. Finally, Shaker Investments LLC OH grew its holdings in shares of LeMaitre Vascular by 0.8% during the fourth quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier’s stock worth $1,285,000 after purchasing an additional 112 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

LMAT has been the topic of a number of research analyst reports. Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Wells Fargo & Company began coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price target for the company. Lake Street Capital boosted their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Finally, StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.25.

LeMaitre Vascular Stock Up 1.7 %

Shares of LMAT stock opened at $86.62 on Thursday. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 47.33, a P/E/G ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 12-month low of $62.39 and a 12-month high of $109.58. The firm has a fifty day moving average of $92.25 and a 200-day moving average of $94.31.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. On average, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were issued a $0.20 dividend. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. The ex-dividend date of this dividend was Thursday, March 13th. This represents a $0.80 annualized dividend and a dividend yield of 0.92%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 41.24%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares in the company, valued at $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.